Susquehanna International Group
TVRD

Susquehanna International Group’s Tvardi Therapeutics TVRD Stock Holding History

Susquehanna International Group’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-317
Closed -$56K – 13346
2023
Q1 		$56K Sell
317
-339
-52% -$114K ﹤0.01% 11647
2022
Q4 		$253K Sell
656
-1,180
-64% -$448K ﹤0.01% 9513
2022
Q3 		$619K Buy
1,836
+736
+67% +$267K ﹤0.01% 7905
2022
Q2 		$362K Sell
1,100
-17
-2% -$5.96K ﹤0.01% 9046
2022
Q1 		$488K Sell
1,117
-2,272
-67% -$933K ﹤0.01% 9055
2021
Q4 		$1.49M Sell
3,389
-1,025
-23% -$515K ﹤0.01% 6238
2021
Q3 		$2.46M Buy
4,414
+383
+10% +$192K ﹤0.01% 5393
2021
Q2 		$2.07M Buy
4,031
+898
+29% +$569K ﹤0.01% 5843
2021
Q1 		$2.45M Sell
3,133
-1,992
-39% -$1.36M ﹤0.01% 5423
2020
Q4 		$2.79M Sell
5,125
-369
-7% -$193K ﹤0.01% 4426
2020
Q3 		$2.52M Sell
5,494
-9
-0.2% -$5.23K ﹤0.01% 4175
2020
Q2 		$3.39M Buy
5,503
+1,928
+54% +$1.06M ﹤0.01% 3602
2020
Q1 		$1.7M Sell
3,575
-3,914
-52% -$2.13M ﹤0.01% 4271
2019
Q4 		$4.34M Buy
7,489
+3,889
+108% +$2.73M ﹤0.01% 3177
2019
Q3 		$2.37M Sell
3,600
-6,272
-64% -$5.21M ﹤0.01% 3877
2019
Q2 		$7.64M Buy
9,872
+3,178
+47% +$2.23M ﹤0.01% 2188
2019
Q1 		$4.73M Buy
6,694
+1,250
+23% +$748K ﹤0.01% 2521
2018
Q4 		$2.55M Sell
5,444
-217
-4% -$140K ﹤0.01% 3159
2018
Q3 		$4.88M Sell
5,661
-9,628
-63% -$6.95M ﹤0.01% 2723
2018
Q2 		$10.5M Buy
15,289
+1,156
+8% +$588K ﹤0.01% 1880
2018
Q1 		$6.3M Buy
14,133
+3,336
+31% +$1.62M ﹤0.01% 2256
2017
Q4 		$4.76M Sell
10,797
-4,300
-28% -$1.96M ﹤0.01% 2588
2017
Q3 		$7.44M Sell
15,097
-7,192
-32% -$3.6M ﹤0.01% 2062
2017
Q2 		$12.3M Buy
22,289
+14,372
+182% +$9.12M 0.01% 1541
2017
Q1 		$5.24M Buy
7,917
+6,745
+576% +$3.6M ﹤0.01% 2312
2016
Q4 		$392K Buy
+1,172
New +$376K ﹤0.01% 7458
2016
Q2 		– Sell
-314
Closed -$70K – 9467
2016
Q1 		$70K Buy
+314
New +$93.8K ﹤0.01% 8575
2015
Q4 		– Sell
-308
Closed -$159K – 10084
2015
Q3 		$159K Buy
+308
New +$206K ﹤0.01% 8881

Other funds holding TVRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group's TVRD Position: Q1 2025 in Review

Susquehanna International Group sold out of Tvardi Therapeutics (TVRD) in Q1 2025, closing a stake of 39,262 shares — an estimated $721K sold.

Susquehanna International Group first reported a position in TVRD in Q4 2014 and held it in 37 quarters. The position peaked at $18.4M in Q1 2017. 33 funds tracked by Wall St. Rank hold TVRD as of Q1 2025.

  • Susquehanna International Group reported no remaining Tvardi Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Susquehanna International Group sold 39,262 Tvardi Therapeutics shares in Q1 2025, an estimated $721K.
  • Susquehanna International Group first reported a position in Tvardi Therapeutics in Q4 2014 and held it in 37 quarters.
  • Susquehanna International Group's Tvardi Therapeutics position peaked at $18.4M in Q1 2017.
  • 33 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2025.

Based on Susquehanna International Group's 13F filing for Q1 2025, filed 14 May 2025.